The Third Central Clinical College of Tianjin Medical University, Tianjin, China.
Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Tianjin, China.
J Matern Fetal Neonatal Med. 2023 Dec;36(2):2257837. doi: 10.1080/14767058.2023.2257837.
To evaluate the impact of timing combined immunoprophylaxis on mother-to-child transmission (MTCT) of the hepatitis B virus (HBV) in pregnant women living with hepatitis B. A retrospective cohort study was included HBsAg-positive pregnant women who delivered full-term at Tianjin Third Central Hospital from January 2019 to December 2021. The objective of this study is to determine whether early administration of hepatitis B immune globulin (HBIG) and the first dose of hepatitis B vaccination after birth can further improve protection. A total of 694 pregnant women living with hepatitis B were included; 93 infants from these mothers were lost to follow-up [including moving ( = 21), emigrating ( = 26), changing contact information ( = 27), and other reasons ( = 19)], leaving 601 infants for analysis. The incidence in babies born to mothers with hepatitis B was 1.50% (9/601). Based on the different timing of combined immunoprophylaxis administration after birth, 601 infants were divided into two groups (within 2 h and within 2-12 h). The incidence in babies born to mothers with hepatitis B were 0.32% (1/308) and 2.73% (8/293) for infants who received combined immunoprophylaxis within 2 h and between 2 and 12 h of birth, respectively ( = 0.037). The infection incidence of infants born to HBeAg-positive mothers and HBeAg-positive mothers who did not receive antiviral treatment during pregnancy was lower in the 2-h group compared to the 2-12 h group (0.72% vs. 5.84%, = 0.04 and 1.20% vs. 9.46%, = 0.047). : Using combined immunoprophylaxis as soon as possible (within two hours of birth) may protect against MTCT of HBV more.
评价联合免疫预防策略对乙型肝炎病毒（HBV）母婴传播（MTCT）的影响，纳入 2019 年 1 月至 2021 年 12 月在天津市第三中心医院分娩的 HBsAg 阳性孕妇的回顾性队列研究。本研究的目的是确定在婴儿出生后尽早给予乙型肝炎免疫球蛋白（HBIG）和第一剂乙型肝炎疫苗是否能进一步提高保护率。共纳入 694 例乙型肝炎病毒感染孕妇，其中 93 例婴儿失访（包括搬迁[=21]、移民[=26]、联系方式变更[=27]和其他原因[=19]），共 601 例婴儿进行分析。乙型肝炎母亲所生婴儿的发生率为 1.50%（9/601）。根据出生后联合免疫预防策略的不同时机，将 601 例婴儿分为两组（2 小时内和 2-12 小时内）。乙型肝炎母亲所生婴儿的发生率分别为 0.32%（1/308）和 2.73%（8/293）（=0.037）。未接受抗病毒治疗的 HBeAg 阳性母亲和 HBeAg 阳性母亲所生婴儿，在 2 小时组的感染发生率低于 2-12 小时组（0.72%比 5.84%，=0.04 和 1.20%比 9.46%，=0.047）。尽快（出生后 2 小时内）使用联合免疫预防策略可能更能预防 HBV 的母婴传播。
